- Home
- Products
- Customized ADCs
- NOTCH2
- Anti-NOTCH2 (Tarextumab)-MC-MMAF ADC
Anti-NOTCH2 (Tarextumab)-MC-MMAF ADC (CAT#: ADC-W-2218)
This ADC product is comprised of an anti-NOTCH2 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- NOTCH2
- Alternative Names
- NOTCH2; notch 2; Notch (Drosophila) homolog 2 , Notch homolog 2 (Drosophila); neurogenic locus notch homolog protein 2; Notch homolog 2; hN2; AGS2; HJCYS;
- Target Entrez Gene ID
- 4853
- Target UniProt ID
- Q04721
- Overview
- This gene encodes a member of the Notch family. Members of this Type 1 transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types. Notch family members play a role in a variety of developmental processes by controlling cell fate decisions. The Notch signaling network is an evolutionarily conserved intercellular signaling pathway which regulates interactions between physically adjacent cells. In Drosophilia, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signaling pathway that plays a key role in development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remain to be determined. This protein is cleaved in the trans-Golgi network, and presented on the cell surface as a heterodimer. This protein functions as a receptor for membrane bound ligands, and may play a role in vascular, renal and hepatic development. Two transcript variants encoding different isoforms have been found for this gene.
- Overview
- Human Anti-NOTCH2 IgG2-kappa antibody, Tarextumab
- Generic name
- Tarextumab
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IL4 (Pascolizumab)-MC-MMAF ADC (CAT#: ADC-W-1378)
- Anti-BSG (Gavilimomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-721)
- Anti-ICAM1 (Enlimomab)-SPDB-DM4 ADC (CAT#: ADC-W-1209)
- Anti-TAG-72 (Anatumomab)-MC-MMAF ADC (CAT#: ADC-W-2176)
- Anti-PVRL4 (Enfortumab vedotin)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2400)
- Anti-ACVR2B (Bimagrumab)-MC-MMAF ADC (CAT#: ADC-W-652)
- Anti-MSLN (Amatuximab)-SPDB-DM4 ADC (CAT#: ADC-W-1593)
- Anti-CD22-SMCC-DM1 ADC (CAT#: ADC-W-2527)
- Anti-FOLR1-S-S-Dox ADC (CAT#: ADC-W-602)
- Anti-TNFRSF8-VC-MMAF ADC-12 (CAT#: ADC-W-345)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2218. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2221 | Anti-NOTCH2 (Tarextumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2220 | Anti-NOTCH2 (Tarextumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2216 | Anti-NOTCH2 (Tarextumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2217 | Anti-NOTCH2 (Tarextumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2219 | Anti-NOTCH2 (Tarextumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-515 | Anti-EGFR-Mc-MMAF ADC-5 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-485 | Anti-EphA2-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-517 | Anti-TM4SF1-Mc-LP2 ADC-1 | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-452 | Anti-CD70-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
| ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.